XML 24 R17.htm IDEA: XBRL DOCUMENT
v3.20.1

Goodwill and Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | Goodwill and Intangible Assets The following sets forth goodwill and intangible assets by major asset class:
|  |  | December 31, 2019 |  | December 31, 2018
| Weighted Average Useful Life (Yrs) | Gross |  | Accumulated Amortization |  | Net Book Value |  | Gross |  | Accumulated Amortization |  | Net Book Value
Indefinite lived: |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill(a) |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |
Definite lived: |  |  |  |  |  |  |  |  |  |  |  |  |
Patents | 10 |  | 5,802,528 |  |  | (5,802,528 | ) |  | — |  |  | 5,802,528 |  |  | (5,742,079 | ) |  | 60,449 |
Licenses | 10 |  | 1,323,761 |  |  | (1,248,104 | ) |  | 75,657 |  |  | 1,323,761 |  |  | (1,219,357 | ) |  | 104,404 |
CELLECTRA®(b) | 8 |  | 8,106,270 |  |  | (8,106,270 | ) |  | — |  |  | 8,106,270 |  |  | (7,679,190 | ) |  | 427,080 |
GHRH(b) | 11 |  | 335,314 |  |  | (335,314 | ) |  | — |  |  | 335,314 |  |  | (303,630 | ) |  | 31,684 |
Bioject (c) | 12 |  | 5,100,000 |  |  | (2,175,556 | ) |  | 2,924,444 |  |  | 5,100,000 |  |  | (1,882,222 | ) |  | 3,217,778 |
Other(d) | 18 |  | 4,050,000 |  |  | (3,356,250 | ) |  | 693,750 |  |  | 4,050,000 |  |  | (3,131,250 | ) |  | 918,750 |
Total intangible assets | 11 |  | 24,717,873 |  |  | (21,024,022 | ) |  | 3,693,851 |  |  | 24,717,873 |  |  | (19,957,728 | ) |  | 4,760,145 |
Total goodwill and intangible assets |  |  | $ | 35,231,244 |  |  | $ | (21,024,022 | ) |  | $ | 14,207,222 |  |  | $ | 35,231,244 |  |  | $ | (19,957,728 | ) |  | $ | 15,273,516 |
(a) | Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for $3.9 million, $6.2 million and $400,000, respectively.
(b) | CELLECTRA® and GHRH are developed technologies which were recorded from the acquisition of VGX.
(c) | Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.
(d) | Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.
Aggregate amortization expense on intangible assets was $1.1 million, $1.2 million and $1.6 million for the years ended December 31, 2019, 2018 and 2017, respectively. Amortization expense related to intangible assets at December 31, 2019 is expected to be incurred as follows:
Year ending December 31, |
2020 | $ | 547,081 |
2021 | 520,414 |
2022 | 492,818 |
2023 | 275,760 |
2024 | 253,333 |
Thereafter | 1,604,445 |
| $ | 3,693,851 |
There were no impairment or impairment indicators present and no losses were recorded during the years ended December 31, 2019, 2018 and 2017, respectively.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration